MetaCap

ImmuCell (ICCC) vs Achieve Life Sciences (QUIT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Achieve Life Sciences is the larger company by market cap ($573.2 million vs $99.3 million), about 5.8 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ICCC+12.58%QUIT-25.87%
+20%-4%-28%
Aug 17, 20261 yearNov 20, 2026
ICCC+8.55%QUIT-30.41%
+10%-11%-32%
Aug 17, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ICCC versus QUIT key metrics
MetricICCCQUIT
Share price$10.92$5.56
Market cap$99.28M$573.25M
1-day change-2.41%-5.28%
YTD return+77.56%—
1-year return+133.33%—
5-year return+18.70%—
P/E ratio (TTM)57.47—
EPS (TTM)$0.19$-1.71
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$27.64M—
Revenue growth (YoY)+4.34%—
Net income (latest FY)$-1.04M$-54.65M
Gross margin41.40%—
Operating margin5.97%—
Net margin-3.76%—
52-week high$12.10$8.64
52-week low$4.67$2.62
Distance from 52-week high-9.75%-35.65%
Analyst consensus—strong_buy
Avg. price target upside—+162.23%
Average volume13.44K1.38M
Shares outstanding9.09M103.10M
Employees7328
SectorHealth CareHealth Care
IndustryBiotechnology: In Vitro & In Vivo Diagnostic SubstancesBiotechnology: In Vitro & In Vivo Diagnostic Substances

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Achieve Life Sciences is about 5.8 times larger than ImmuCell by market value ($573.25M vs $99.28M).

About ImmuCell

ICCC stock →

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 73 employees

About Achieve Life Sciences

QUIT stock →

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 28 employees

ICCC vs QUIT FAQ

Which is bigger, ImmuCell or Achieve Life Sciences?

Achieve Life Sciences (QUIT) is larger, with a market capitalization of $573.25M compared with $99.28M for ImmuCell (ICCC).

Are ImmuCell and Achieve Life Sciences in the same industry?

Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.

More comparisons